Pharmaceuticals

Pfizer Invests $43 Billion to Battle Cancer

Pfizer Invests $43 Billion to Battle Cancer

Pfizer Inc. and Seagen Inc. has announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion. The Boards of Directors of both …

Pfizer Invests $43 Billion to Battle Cancer Read More »

Novartis supports Ukraine one year on

Novartis supports Ukraine one year on

Novartis unwavering in support one year on from the start of the war in Ukraine  Novartis has marked the first anniversary of the war in Ukraine. Novartis continues to condemn the ongoing conflict, while the unwavering support to those impacted continues through humanitarian aid, financial donations and critical medicines.  Novartis, a global medicines company, has …

Novartis supports Ukraine one year on Read More »

US FDA accepts Sandoz Biologics License Application

US FDA accepts Sandoz Biologics License Application

Sandoz Biologics License Application for proposed biosimilar denosumab accepted by US FDA  Sandoz, a global leader in off-patent (generic and biosimilar) medicines, has announced that the US Food and Drug Administration (US FDA) has accepted its Biologics License Application (BLA) for proposed biosimilar denosumab.  The application includes all indications covered by the reference medicines Prolia® (denosumab) …

US FDA accepts Sandoz Biologics License Application Read More »

Novartis provides update on Phase III STAND trial assessing crizanlizumab

Update on Phase III STAND trial assessing crizanlizumab

Novartis provides update on Phase III STAND trial assessing crizanlizumab The preliminary results from the ongoing global phase III study STAND indicate no statistically significant difference between crizanlizumab 5mg/kg or crizanlizumab 7.5mg/kg and placebo in annualized rates of vaso-occlusive crises (pain crises) leading to a healthcare visit over the first-year post randomization. These findings are …

Update on Phase III STAND trial assessing crizanlizumab Read More »

Pfizer Expands ‘An Accord for a Healthier World’ Product

Pfizer Expands ‘An Accord for a Healthier World’ Product

Pfizer Expands ‘An Accord for a Healthier World’ Product Offering to Include Full Portfolio for Greater Benefit to 1.2 Billion People in 45 Lower-Income Countries  Pfizer Inc. has announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccines for which it has …

Pfizer Expands ‘An Accord for a Healthier World’ Product Read More »